Oncternal Therapeutics (FRA:GTU) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Oncternal Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Oncternal Therapeutics's Free Cash Flow for the three months ended in Mar. 2024 was €-6.84 Mil. Oncternal Therapeutics's Revenue for the three months ended in Mar. 2024 was €0.00 Mil. Therefore, Oncternal Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, Oncternal Therapeutics's current FCF Yield % is -106.31%.

The historical rank and industry rank for Oncternal Therapeutics's FCF Margin % or its related term are showing as below:

FRA:GTU's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -143.92
* Ranked among companies with meaningful FCF Margin % only.

Oncternal Therapeutics FCF Margin % Historical Data

The historical data trend for Oncternal Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncternal Therapeutics FCF Margin % Chart

Oncternal Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

Oncternal Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Oncternal Therapeutics's FCF Margin %

For the Biotechnology subindustry, Oncternal Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncternal Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncternal Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Oncternal Therapeutics's FCF Margin % falls into.

Oncternal Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Oncternal Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-29.494	/	0
	=	%

Oncternal Therapeutics's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-6.843	/	0
	=	%

Oncternal Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Oncternal Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncternal Therapeutics (FRA:GTU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncternal Therapeutics Inc (FRA:GTU) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

ONCT:USA

Address

12230 El Camino Real, Suite 230, San Diego, CA, USA, 92130

Website

https://www.oncternal.com

Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.

Oncternal Therapeutics (FRA:GTU) Headlines

No Headlines